Genome Medicine | Article collections | Pharmacogenomics

Genome Medicine | Article collections | Pharmacogenomics

Pharmacogenomics

Edited by: Prof Matthias Schwab

Collection published: 29 November 2012

Last updated: 11 January 2013

Efforts to predict and monitor drug response in individuals and in the population have increased markedly over the past few years, but there is a need for replication, targeted resequencing and functional understanding, and for translation of pharmacogenomics research into the clinic. Genome Medicine presents a series devoted to pharmacogenomics, edited by Matthias Schwab from IKP Stuttgart, Germany, to highlight this important and fast-moving field.

Research   Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 Anne T Nies, Mikko Niemi, Oliver Burk, Stefan Winter, Ulrich M Zanger, Bruno Stieger, Matthias Schwab, Elke Schaeffeler Genome Medicine 2013, 5:1 (11 January 2013) Abstract | Provisional PDF | PubMed |  Editor’s summary Variations at the SLCO1B1 locus affect hepatic OATP1B1 expression, and the variant c.388A>G strongly alters this expression, which has functional consequences for atorvastatin plasma levels.

Review  

Pharmacogenomics of hepatitis C infections: personalizing therapy

David R Booth, Golo Ahlenstiel, Jacob George Genome Medicine 2012, 4:99 (26 December 2012)

Abstract | Full text | PDF | PubMed |  Editor’s summary

David Booth and colleagues review the pharmacogenetic applications of IL28B genotyping, the only genetic variant currently used diagnostically to predict drug response to hepatitis C virus.

Research  

Assessing the metabolic effects of prednisolone in healthy volunteers using urine metabolic profiling

Sandrine Ellero-Simatos, Ewa Szymanska, Ton Rullmann, Wim HA Dokter, Raymond Ramaker, Ruud Berger, Thijs MP van Iersel, Age K Smilde, Thomas Hankemeier, Wynand Alkema Genome Medicine 2012, 4:94 (30 November 2012)

Abstract | Provisional PDF | PubMed |  Editor’s summary

Metabolomics shows that the off-target effects of the common anti-inflammatory drug prednisolone are dosage and time dependent; this approach is likely to be widely used in drug research.

Review  

Pharmacogenomics of chemotherapeutic susceptibility and toxicity

Erika L Moen, Lucy A Godley, Wei Zhang, M Eileen Dolan Genome Medicine 2012, 4:90 (30 November 2012)

Abstract | Full text | PDF | PubMed |  Editor’s summary

Eileen Dolan and colleagues review the contribution of germline genetic variation to chemotherapeutic toxicity and response and discuss the use of lymphoblastoid cell lines in pharmacogenomic studies.

Editorial  

Pharmacogenomics: a key component of personalized therapy

Matthias Schwab, Elke Schaeffeler Genome Medicine 2012, 4:93 (29 November 2012)

Abstract | Full text | PDF | PubMed |  Editor’s summary

Matthias Schwab and Elke Schaeffeler reflect on how 'omics' approaches have revolutionized the understanding of disease susceptibility and pathophysiology, leading to potential new therapies.

Opinion  

Designing a post-genomics knowledge ecosystem to translate pharmacogenomics into public health action

Edward S Dove, Samer A Faraj, Eugene Kolker, Vural Özdemir Genome Medicine 2012, 4:91 (29 November 2012)